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Summary
Gaucher disease (GD) is one of the most prevalent ly-
sosomal storage disorders and one of the rare genetic
diseases now accessible to therapy. Outside the Ashke-
nazi Jewish community, a high molecular diversity is
observed, leaving ∼30% of alleles undetected. Never-
theless, very few exhaustive methods have been devel-
oped for extensive gene screening of a large series of
patients. Our approach for a complete search of mu-
tations was the association of fluorescent chemical cleav-
age of mismatches with a universal strand-specific la-
beling system. The glucocerebrosidase (GBA) gene was
scanned by use of a set of six amplicons, comprising 11
exons, all exon/intron boundaries, and the promoter re-
gion. By use of this screening strategy, the difficulties
due to the existence of a highly homologous pseudogene
were easily overcome, and both GD mutant alleles were
identified in all 25 patients studied, thus attesting to a
sensitivity that approaches 100%. A total of 18 different
mutations and a new glucocerebrosidase haplotype were
detected. The mutational spectrum included eight novel
acid b-glucosidase mutations: IVS2 G(1)rT, I119T,
R170P, N188K, S237P, K303I, L324P, and A446P.
These data further indicate the genetic heterogeneity of
the lesions causing GD. Established genotype/phenotype
correlations generally were confirmed, but notable dis-
parities were disclosed in several cases, thus underlining
the limitation in the prognostic value of genotyping. The
observed influence of multifactorial control on this mon-
ogenic disease is discussed.
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Introduction
Gaucher disease (GD), the most frequent lysosomal stor-
age disorder, is an autosomal recessive disease charac-
terized by deficiency of acid b-glucosidase (glucocere-
brosidase, E.C.3.2.1.45) (Beutler and Grabowski 1995;
Grabowski et al. 1996). The enzymatic defect leads to
systemic accumulation of its substrate, glucosylceramide
(also named “glucocerebroside”), mainly within cells of
the monocyte/macrophage lineage, resulting in the clin-
ical manifestations. GD, characterized by a large and
continually expanding phenotypic heterogeneity (Sid-
ransky and Ginns 1993; Abrahamov et al. 1995), con-
ventionally is classified into three clinical types, on the
basis of the absence (type 1) or presence and severity
(types 2 and 3) of primary CNS involvement. Type 1
GD (MIM 230800) is the most common form, with a
markedly heterogeneous clinical expression, with respect
to age at onset, progression, and severity of clinical man-
ifestations. Common features are splenomegaly, frequent
concurrent liver enlargement, and consequent anemia
and thrombocytopenia. In severe cases, orthopedic com-
plications occur. The much rarer clinical types, 2 (MIM
230900) and 3 (MIM 231000), differ from type 1 in
that patients show neurological involvement; type 2 usu-
ally manifests soon after birth, whereas type 3 may ap-
pear as late as the 3d decade of life (Brady et al. 1993).
The full-length cDNA and genomic sequences encoding
human glucocerebrosidase have been isolated and char-
acterized (Sorje et al. 1985; Horowitz et al. 1989; Beutler
et al. 1992). The active gene (GBA), localized to the
long arm of chromosome 1 at 1q21, contains 11 exons
spanning 8 kb. A highly homologous pseudogene
(psGBA), transcribable into mRNA but unable to pro-
duce a functional enzyme, is located 16 kb downstream
from the active gene (Horowitz et al. 1989). Cloning of
the GBA gene has allowed identification of the nature
of mutations underlying the enzyme deficiency in GD
patients. Various studies have demonstrated the molec-
ular heterogeneity of acid b-glucosidase deficiency.More
than 70 gene alterations responsible for the disease have
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Figure 1 Principle of the FAMA method using universal fluo-
rescent primers. For each region, the first PCR is performed by use of
long-tailed primers consisting of two portions: the 3′ half has the nec-
essary homology for a specific amplification of the acid b-glucosidase
functional gene, and the 5′ half has been chosen for minimal homology
to any sequence in human-genome databases (part I) and will serve
as a universal template for the second step of amplification with prim-
ers labeled, at their 5′ ends, with different fluorophores (6-FAM and
HEX for the sense and the antisense strand, respectively) (part II). In
the case shown (part III), the heterozygous CrT transition gives rise
to two heteroduplex mismatches (C-A and T-G). By means of chemical
modifications by HA and osmium tetroxide, which react with mis-
paired cytosines and thymines, respectively (part IV), cleavage with
piperidine ensures detection of two cleavage products for each point
mutation and maximizes precision in the positioning of the sequence
heterogeneity (part V). In the illustrated example, a cleavage peak will
be detected on the sense strand, at the same location, for each mod-
ification reaction (HA and osmium tetroxide chemistries).
been identified (Beutler and Gelbart 1996). The relative
incidence of glucocerebrosidase mutations has been
studied extensively in the Ashkenazi Jewish popula-
tion(s), in which four defects (N370S, 84insG, L444P,
and IVS2 G[1]rA) account for 90% of the disease-
causing changes (Beutler et al. 1993). A more hetero-
geneous distribution of mutations within the non-Jewish
population(s) has emerged, and mutation frequencies in
defined populations have been reported in recent studies
(Amaral et al. 1994; Cormand et al. 1995; Boot et al.
1997; Le Coutre et al. 1997). However, all these studies
have focused on common mutations, leaving ∼30% of
the alleles undetected in non-Jewish populations.
Two main reasons may justify a full investigation of
mutations. First, identification of novel mutations may
prove useful for genetic counseling and prenatal diag-
nosis in families in which these mutations are found
(Zimran et al. 1995), since enzymology does not provide
accurate carrier detection (Daniel and Glew 1982); sec-
ond, such an investigation may help to further delineate
genotype/phenotype correlations and disparities.
Very few exhaustive mutational analyses of the GBA
gene have been reported; many authors deliberately
chose to scan only a limited number of exons and/or
mentioned a lack of sensitivity that is hardly acceptable
in a medical context. Chemical cleavage of mismatches
(CCM), based on cleavage of heteroduplex DNA at mis-
paired bases and sizing of the truncated DNA strands,
has proved effective in the screening of large DNA
regions (Cotton et al. 1988). The possibility of analyzing
large fragments allows more flexibility in the design of
primers. Adaptation to fluorescence-based detection sys-
tems, through a nested PCR, in a procedure named
“fluorescence-assisted mismatch analysis” (“FAMA”)
has simplified the method and has maximized positional
precision and diagnostic accuracy (Verpy et al. 1994;
Germain et al. 1996). However, the high cost of pro-
ducing new, fluorescently tagged specific primers for
each of the amplicons prompted us to design and develop
a single, universal priming system for the highly specific
fluorescent labeling of DNA-amplification products (fig.
1). In this study, we demonstrated the advantages of this
universal strand-specific bifluorescent-labeling strategy
combined with CCM, by completing an exhaustive mu-
tation detection in 25 GD patients. Eight novel muta-
tions and a newGBA haplotype are described, genotype/
phenotype correlations and disparities are delineated,
and the influence of multifactorial factors is discussed.
Patients and Methods
Patients
The 25 unrelated patients (10 females and 15 males;
4–73 years of age) in this study were diagnosed by clin-
ical examination and by determination of 4-methyl um-
belliferyl-b-glucosidase activity in leukocytes. The phy-
sicians who contributed patient blood samples to our
study provided clinical information concerning their pa-
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Figure 2 Screening strategy and distribution of mutations identified in this report. The structure of the acid b-glucosidase gene is shown,
with exons represented by boxes and introns represented by lines. Blackened bars beneath the gene indicate the regions with absence of homology
with the pseudogene. PCR-amplified fragments are represented with their terminal fluorophores, 6-FAM (circles) or HEX (squares), at the
bottom of the figure. The locations of all mutations identified in this report are shown above the schematic diagram of the gene. The novel
mutations are indicated in boldface, italic type.
tients. The results of examinations of our patients have
not been published previously. The geographic origin of
the patients is spread throughout different regions in
France; therefore, this group’s panel can be considered
to be representative of the French population.
Amplification of Genomic DNA Fragments, by Use of
a Universal Fluorescent-Labeling System
Genomic DNA for mutation analysis was prepared
from peripheral blood leukocytes or lymphoblastoid cell
lines by standard procedures. Six fragments covering the
acid b-glucosidase gene were amplified (fig. 2). For each
region, 500 ng of genomic DNA was used for a first
round of PCR amplification, using the unlabeled chi-
meric oligonucleotide primers listed in table 1. These
primers were chosen to specifically amplify the active
gene and not the pseudogene and were extended by uni-
versal sequences at their 5′ ends. Since this labeling strat-
egy requires that the first PCR be free of spurious am-
plification products, high specificity was obtained by
priming at sites with a particularly rare sequence com-
position. This was achieved by choosing rare sequences
for the 3′ end of each nonfluorescent primer in human-
genome databases (Griffais et al. 1991). PCR products
were checked on a 1% agarose gel, and a 1/100 dilution
was submitted to a second round of PCR, using the
universal primers complementary to the universal ex-
tensions of the chimeric primers, labeled at their 5′ ends
with 6-carboxyfluoresceine (for the forward primer) and
hexachlorofluoresceine (for the reverse primer) fluores-
cent dyes (fig. 1). These universal primers were designed,
by use of PC-Rare software, to have a unique sequence
exhibiting minimal homology to any sequence found in
current human–DNA-sequence databases (Griffais et al.
1991).
Fluorescent CCM
Heteroduplexes were made from a normal control and
from the patients’ labeled DNA, by boiling—for 5 min
in 200 ml of 0.3 M NaCl, 3.5 mM MgCl2, and 3 mM
Tris-HCl, pH 7.7—1 pmol of bichrome PCR fragments,
which then were placed in a water bath at 65C over-
night. The heteroduplexes were ethanol precipitated af-
ter addition of 60 mg glycogen (Boehringer) as a carrier
and were resuspended in 24 ml distilled water (or in 10
mMTris HCl, pH 7.5).Modification reactions thenwere
performed by incubating 6 ml of DNA, at 37C for 45
min, with 20 ml of a freshly thawed 3.8-M hydroxyla-
mine (HA) working solution, whereas another aliquot
of 6 ml was treated, for 15 min at room temperature,
with 9 ml of reaction buffer (6.94% pyridine, 1.388 mM
Na2EDTA, and 13.88 mM Hepes, pH 8.0) and 10 ml of
1% osmium tetroxide, in a total volume of 25 ml in
silanized tubes (aliquots of both the HA working solu-
tion and the 1% osmium tetroxide stock solution were
stored at80C for up to 6 mo, thus removing potential
hazards associated with repeated preparation). The
modification reactions were blocked by adding 200 ml
of ice-cold stop solution (0.3 M sodium acetate, pH 5.2,
and 0.1 mM Na2EDTA), and the nucleic acids were eth-
anol precipitated in a dry ice/ethanol bath. Pellets were
washed once with 70% ethanol, resuspended by vor-
texing in 50 ml of freshly diluted 1-M piperidine, and
incubated 20 min at 90C. The nucleic acids were pre-
cipitated, washed twice in 70% ethanol, vacuum dried,
and, when necessary, stored at20C until loading. Pel-
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Table 1
Parameters for Amplification of the Acid b-Glucosidase Gene Fragments
Exon(s) and/or
Fragment Primer Sequence (5′r3′)a
Acid b-Glucosi-
dase Gene
Coordinates
Size of
Amplified
Product
(bp)
First PCR:
1 and 2:
Forward ggACCgTTAgTAACCgAC-CACACCTCTATAGGGCAAAGACTG 75–98 1,266
Reverse AgTCggATAgCTAgTCgT-GAGGCAGAGGTTGGAATGAGCCAA 1282–1305
3 and 4:
Forward ggACCgTTAgTAACCgAC-AACAgAgTCTTACTCTgTTgCCTggg 1235–1260 1,066
Reverse TCggATAgCTAgTCgT-TgAggCAggAgAATCACTATAgCC 2242–2265
5 and 6:
Forward ggACCgTTAgTAACCgAC-ACTATTAGGACTGGCAAGTG 2961–2980 931
Reverse TCggATAgCTAgTCgT-TACAGTGAGTGAAGATGGCG 3837–3856
7:
Forward ggACCgTTAgTAACCgAC-GGGTTTCGCCAGGCTGTTCTCG 3967–3988 882
Reverse AgTCggATAgCTAgTCgT-GAGATGGAGTCTCGCTCAGCCT 4792–4813
8 and 9:
Forward ggACCgTTAgTAACCgAC-AAATTAGCTGGGTGTGGCACCCGT 4944–4967 1,268
Reverse AgTCggATAgCTAgTCgT-GTCACTTCCTGCCTCCATGGTGCA 6153–6176
10 and 11:
Forward ggACCgTTAgTAACCgAC-TGGGGTGGGTCCGTGGGTGG 6296–6315 1,191
Reverse AgTCggATAgCTAgTCgT-GTCTCCATCCAGCGGGCAAC 7432–7451
Second PCR:
Forward 6-FAM-ggggACCgTTAgTAACCgAC Universal primer
Reverse HEX-ggAgTCggATAgCTAgTCgT Universal primer
a Universal extensions and primers are underlined.
lets were dissolved in a solution of 6 ml deionized for-
mamide and 50 mMNa2EDTA, and 3 ml of each sample,
mixed with 0.5 ml of fluorescence-labeled size standard
(GS2500 ROX; ABI), was heated to 95C for 5 min and
kept on ice until loading on a 6% polyacrylamide/urea
gel on an automated ABI 373 DNA sequencer. Electro-
phoresis was performed overnight for up to 20 h in 1
# Tris borate–EDTA, at 35 W, and data were collected
and analyzed by use of the appropriate GENESCAN
software (ABI). For a sizing requirement of the software,
the 3′ ends of nonfluorescent primers were positioned
directly at a distance of x70 bp from the target
sequence.
Sequencing
When cleavage peaks were encountered in FAMA, in-
dependently PCR-amplified fragments of the corre-
sponding region were sequenced on both strands, to de-
termine the precise nature of the mutation. PCR
products were purified by use of the QIAquick Spin PCR
purification kit (Qiagen), to remove unincorporated oli-
gonucleotide primers. All sequencing reactions were
performed on an automated ABI 373A DNA sequencer
with the Prism DyeDeoxy Terminator sequencing
kit (ABI), in accordance with the manufacturer’s
recommendations.
Nomenclature
The designations for the mutations refer to the posi-
tion of the amino acid substitution, where amino acid
1 is the amino terminus of the mature protein. The
cDNA base numbers refer to the position of the nucle-
otide in the cDNA, where nucleotide 1 is the A of the
first ATG (Genbank/European Molecular Biology Lab-
oratory [EMBL] accession number M11080). The ge-
nomic designations are based on the updated acid b-
glucosidase Genbank/EMBL sequence (accession num-
ber J03059), from which the first 875 nucleotides in the
5′ UTR have been deleted. The first nucleotide of exon
1 is at genomic position 355 (Grace et al. 1997).
Results
Clinical Forms and Geographic Distribution of Affected
Patients
Clinical symptoms, b-glucosidase activities, and gen-
otypes of all patients are presented in table 2. All 25
unrelated patients are of French origin, and only two of
them (patients 1 and 10) are of Ashkenazi Jewish de-
scent. At the time of the study, only two patients had
developed neurological symptoms, establishing that they
had type 3 GD. Since one patient without neurological
symptoms was !15 years of age, final classification (type
Table 2
Clinical Characteristics of Patients with Associated Genotypes
Patient
(Initials)
Present
Age/Age at
Diagnosis
(years) Sex
Clinical Signs
(Treatment) Neuronopathy
GD
Clinical
Type
4Methyl
Umbelliferyl-
b-Glucosidase
Activitya Genotype
1 (MS) 67/29 M Splenomegaly (splenec-
tomy), osteosarcoma
None 1 9 N370S/84insG
2 (CB) 53/9 F Severe hepatosplenome-
galy (splenectomy),
anemia, skeletal
deterioration
None 1 4 N370S/IVS2 G(1)rT
3 (PL) 33/5 M Hepatosplenomegaly, se-
vere pancytopenia
None 1 15 N370S/I119T
4 (MF) 68/65 F Mild splenomegaly, mild
thrombocytopenia
None 1 7 N370S/R120W
5 (MCL) 50/35 F Moderate splenomegaly,
mild hepatomegaly,
thrombocytopenia
None 1 ? N370S/R120W
6 (SL) 26/22 M Pancytopenia, severe
skeletal disease
None 1 4 N370S/R120W
7 (CN) 27/25 M Splenomegaly (splenec-
tomy), hepatomegaly,
thrombocytopenia,
pain
None 1 6 N370S/N188K
8 (BC) 14/4 M Massive splenomegaly,
hepatomegaly, skeletal
deterioration
None 1 17 N370S/S237P
9 (CG) 34/30 M Massive splenomegaly None 1 2 N370S/L324P
10 (GM) 73/65 M Mild splenomegaly, he-
patomegaly,
thrombocytopenia
None 1 18 N370S/N370S
11 (VF) 26/15 F Mild splenomegaly None 1 18 N370S/N370S
12 (MD) ?/? F Unknown None 1 ? N370S/G377S
13 (GS) 24/? F Hepatosplenomegaly,
bone crises, skeletal
deterioration
None 1 10 N370S/rec NciI
14 (FF) 28/23 M Mild hepatosplenome-
galy, no skeletal
complications
None 1 6 N370S/L444Pb
15 (JG) 54/45 M Splenomegaly, hepato-
megaly, thrombocyto-
penia, massive
osteopathy
None 1 6 N370S/L444Pb
16 (JP) 22/3 M Massive splenomegaly,
thrombocytopenia,
skeletal pain
None 1 5 N370S/L444Pb
17 (IA) 32/27 F Splenomegaly, mild
pancytopenia
None 1 9 L444P/R48W
18 (YD) 4/1 M Massive
hepatosplenomegaly
Abnormal eye
movements
1/3 16 L444P/L444Pb
19 (AP) 10/1 F Massive
hepatosplenomegaly
Strabismus,
modified
EEG
3 18 L444P/L444Pb
20 (JG) 36/31 M Mild symptomatology None 1 15 L444P/R463C
21 (ES) 6 (deceased)/1 M Splenomegaly, thrombo-
cytopenia, deceased at
6 years of age despite
enzyme recombinant
therapy
Ataxia,
epilepsy
3 0 rec NciI/V394L
22 (AP) 62/59 M Mild symptomatology None 1 16 R463C/K303I
(continued)
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Table 2 (continued)
Patient
(Initials)
Present
Age/Age at
Diagnosis
(years) Sex
Clinical Signs
(Treatment) Neuronopathy
GD
Clinical
Type
4Methyl
Umbelliferyl-
b-Glucosidase
Activitya Genotype
23 (BS) 19/? M Hepatosplenomegaly,
bone crises, skin
pigmentation
None 1 13 IVS2 G(1)rA/R170P
24 (ML) 49/49 F Massive splenomegaly None 1 19 G377S/G377S
25a (VT) 31/10 F Splenomegaly (splenec-
tomy), severe skeletal
deterioration, con-
fined to wheelchair
None 1 8 A446P/A446P
25b (GT)c 29/? M Asymptomatic None 1 20 A446P/A446P
a Residual enzymatic activities are expressed as the percentage of control values.
b Complex alleles were ruled out.
c Brother of patient 25a.
1 or type 3 GD) had to be postponed. The remaining
patients presented with type 1 GD.
Identification of Unknown Mutations, by FAMA Using
Universal Primers
The 7.6-kb b-glucosidase gene was amplified in six
DNA fragments spanning the whole coding region, all
exon-intron boundaries, the 200 bp 5′ to the transcrip-
tion start site, and 700 bp of the 3′ noncoding region
(fig. 2). No size abnormality was detected when ampli-
fied products were analyzed by agarose-gel electropho-
resis. For all patients, the six bichrome PCR fragments,
shown in figure 2, were studied by fluorescent CCM (i.e.,
FAMA). Direct sequencing of the relevant region was
used to formally verify all detected mutations. This ex-
haustive screening of the acid b-glucosidase gene resulted
in characterization of the genotypes of all 25 patients
(table 2) and identification of eight novel point muta-
tions (IVS2 G[1]rT, I119T, R170P, N188K, S237P,
K303I, L324P, and A446P; fig. 2). Other alleles found
included the three common mutations N370S, L444P,
and 84insG, as well as two frequent glucocerebrosidase
mutant alleles (IVS2 G[1]rA and the complex allele
rec NciI [L444P  A456P  V460V]). The frequent
D409H mutation (Abrahamov et al. 1995) was not ev-
idenced in our series. We also detected five rare, previ-
ously reported mutations (R48W, R120W, G377S,
V394L, and R463C). The identified nucleotide substi-
tutions and the resulting changes at the protein level are
presented in table 3.
Some of the characterized genotypes were of partic-
ular interest. One recurrent genotype was found in three
unrelated patients originating from the same area of
France, namely, Brittany. Screening of patients 4, 5, and
6 demonstrated that they are compound heterozygotes
for the common N370S allele. Unexpectedly, FAMA of
these three patients also revealed the same CrT tran-
sition in exon 5 (fig. 3), changing an arginine (CGG) to
tryptophan (TGG) at position 120 of the mature enzyme
(R120W). Notably, the mutation destroys an MspI re-
striction site, which can be used as a screening strategy.
The surrounding sequence was not that of the pseudo-
gene (fig. 3) and, therefore, not the product of an ex-
tensive unequal crossover, as had been reported else-
where (Latham et al. 1991).
Patient 7 also was a compound heterozygote for the
N370S mutation, with his second allele carrying a TrG
transversion in exon 6, at position 3482 (N188K) in the
genomic sequence. This nucleotide substitution corre-
sponds to the pseudogene sequence at the analogous site
and also has been reported to be part of the aforemen-
tioned complex allele (Latham et al. 1991). However, in
the case of our patient, a crossover event between the
structural gene and the pseudogene was not likely, since
other pseudogene-like substitutions at contiguous sites
were not present. These data were formally controlled
by direct sequencing.
Analysis, by FAMA, of the GBA gene in patient 21
showed a complex allele, thus illustrating the possibility
of using this technique to detect multiple sequence
changes in large DNA fragments (fig. 4). This complex
allele, named “rec NciI,” consists of a single-base sub-
stitution in three different codons: codon 444, Leu
(CTG)rPro (CCG); codon 456, Ala (GCT)rPro (CCT);
and codon 460, Val (GTG)rVal (GTC) (Latham et al.
1990). This mutant allele is identical in sequence to a
region of the pseudogene (Horowitz et al. 1989) and
may be the result of a fusion gene or a gene conversion.
This severely affected type 3 GD patient died at 6 years
of age, despite prolonged enzyme recombinant therapy
that improved the visceral manifestations but not the
neurological ones; his second allele was shown to carry
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Table 3
Novel Mutations Identified in Patients with GD
Patient(s) Designation
cDNA
Position
Genomic
Position Codon Change
Exon or
Intron Amino Acid Change
2 IVS2 G(1)rT ) 1067 ) Intron 2 Splice (AGgtrAGtt)
3 I119T 473 3064 ATCrACC Exon 5 Isoleucine119rthreonine
23 R170P 626 3427 CGTrCCT Exon 6 Arginine170rproline
7 N188K 681 3482 AATrAAG Exon 6 Asparagine188rlysine
8 S237P 826 4182 TCTrCCT Exon 7 Serine237rproline
22 K303I 1025 5252 AAArATA Exon 8 Lysine303risoleucine
9 L324P 1088 5315 CTArCCA Exon 8 Leucine324rproline
25a, 25b A446P 1453 6449 GCArCCA Exon 10 Alanine446rproline
a GrT transversion at position 5924, resulting in a
ValrLeu substitution at codon 394 of the mature
enzyme.
Patient 25a, suffering from a severe type 1 GD, and
her very mildly affected brother presented with striking
phenotypic differences. In both of them, a GrC trans-
version was revealed at position 6449 in exon 10 of the
structural gene, predicting an A446P missense mutation
at the protein level. Despite complete mutation scanning
of the rest of the gene, no other sequence abnormality
was found. In fact, the presence of a normal A446 allele
was excluded in an additional investigation, without ad-
dition of normal control DNA, which failed to reveal
the aforementioned cleavage peak. This strongly sug-
gested either a deletion of the other GBA allele or ho-
mozygosity for the A446P mutation (Dianzani et al.
1991). Further inquiries revealed that these patientswere
the offspring of a consanguineous couple, and sequenc-
ing of the relevant b-glucosidase–gene region in the par-
ents confirmed that both were heteroallelic for A446P.
Amutation (IVS2 G[1]rT) was identified at the con-
sensus donor splice site of intron 2, when theGBA gene
in patient 2 was analyzed. This novel mutation differs
from the already described IVS2 G(1)rA allele, which
is thought to arise from genetic recombination with the
pseudogene (He and Grabowski 1992). The second allele
was shown, by FAMA, to be the N370S common mu-
tation. During this latter mutation search, another se-
quence heterogeneity unexpectedly was evidenced
simultaneously in intron 7 (data not shown). This het-
eroallelism actually corresponded to a polymorphism.
Several other intragenic polymorphic sites (RFLPs) were
investigated subsequently by genomic sequencing or re-
striction cleavage. This led us to document the existence
of a novel GBA haplotype, which has been identified by
6 of the 12 initially described RFLPs. This variant was
found again in another French patient (patient 17), who
carried a different genotype (R48W/L444P).
Discussion
The aim of the present survey was to determine the
precise nature and distribution of mutations in 25 GD
patients and to document the efficiency of FAMA by
chemical cleavage, combined with a new universal prim-
ing system, to screen for unknown mutations.
Screening Strategy
Comparisons of different DNA scanning methods
should provide indications as to the best choice(s) in a
diagnostic context (Grompe 1993; Cotton 1997). Sev-
eral PCR-based technologies have been used for the
screening of the GBA gene, thereby contributing to the
determination of the frequency of recurrent mutations.
Nevertheless, the majority of the studies using these
methods focused on the most common mutations
(N370S, L444P, and 84insG), resulting in ∼30% un-
detected alleles in non-Jewish populations. The most
complete approaches have used SSCP combined with
nested PCR (Sibille et al. 1993) and, more recently, long
PCR (Tayebi et al. 1996). However, very few exhaustive
screenings, for unknown mutations, of the complete
gene in a large series of patients have been performed
by use of these methods, and most authors report a lack
of sensitivity in their screening strategy.
Our approach was to develop an exhaustive screening
method by combining CCM with a universal strand-
specific fluorescent-labeling system. CCM is a powerful
technique with sensitivity approaching 100% (Cotton et
al. 1988). Its potential toxicity was reduced by storage
of both HA and osmium tetroxide in aliquots kept at
80C and by fluorescence labeling of the DNA frag-
ments. Strand-specific fluorescent labeling offers signif-
icant improvements in identification and localization of
mismatches (Verpy et al. 1994; Rowley et al. 1995; Ger-
main et al. 1996). An absolute requirement was to dis-
tinguish between the GBA gene and the pseudogene.
This was achieved by amplification of large DNA frag-
ments, which gives more flexibility in the design of prim-
ers (fig. 2).
Differential DNA-strand fluorescent labeling classi-
cally has been performed by a nested PCR, by use of
region-specific fluorescent primers. However, producing
new, fluorescently tagged primers for each of the am-
plicons studied is costly. Moreover, nested PCR requires
422 Am. J. Hum. Genet. 63:415–427, 1998
Figure 3 Detection of missense point mutation R120W. This CrT transition was found in exon 5 in three unrelated patients (4, 5, and
6). The three fluorescence profiles of the sense strand—indicated here, for convenience, in blue, black, and red—are perfectly superimposed.
This CrT transition gives rise to two different heteroduplexes (C-A and T-G). By means of HA modification and piperidine cleavage, the C-
A mismatch is precisely localized, by the software (as shown by the cross in the table), at a position 125 bp from the 5′ terminal fluorescent
label. Analysis of cleavage signals of very low amplitude, at surrounding sequences, reflects weak but specific modifications at each paired C
residue, thus improving precision in the positioning of the mutation and allowing coamplification of psGBA sequences to be ruled out. Osmium
tetroxide chemistry yielded similar results for the T-G mismatch (not shown).
optimization of yield and quality of the second PCR; we
therefore devised a universal priming strategy to circum-
vent both these aspects (fig. 1). High specificity of am-
plification was obtained by choosing rare sequences for
the 3′ ends of the nonfluorescent primers and by de-
signing each of the two “universal” extensions to have
minimal homology to any sequence found in hu-
man–DNA-sequence databases (Griffais et al. 1991).
Once PCR conditions were determined, the FAMA
method allowed an exhaustive molecular diagnosis of
the GBA gene, with a sensitivity approaching 100%,
since all 50 mutant alleles of the 25 patients were char-
acterized. Conversely, in spite of constant improvements
of sequencing chemistries, direct automated sequencing
does not guarantee complete detection of heterozygous
mutations and requires time-consuming and costly op-
timizations (Kwok et al. 1994), which are not yet suited
to diagnostic tasks (Phelps et al. 1995; Verpy et al. 1996).
Mutation Profile and Haplotype Analysis
Among the 50 alleles studied, 32 (64%) carried the
recurrent mutations N370S, L444P, and 84insG, ac-
counting for 19, 12, and 1 allele(s), respectively. Data
concerning the N370S mutation differ from those from
initial investigations of non-Jewish patients (Beutler and
Gelbart 1993) but agree with frequencies reported for
other European populations (Cormand et al. 1995; Le
Coutre et al. 1997). Thus, the N370S mutation, which
has not been evidenced in a large Japanese series (Ida et
al. 1995), appears to be common in all European pop-
ulations and possibly may have been enriched within the
Ashkenazi community by endogamy. The observed fre-
quency of the L444P mutation (24%) is lower than that
observed in America (Beutler and Gelbart 1993), Israel
(Horowitz et al. 1993), or Asia (Ida et al. 1995) but is
in accordance with results from other studies of Euro-
pean populations (Boot et al. 1997; Le Coutre et al.
1997); no data were available from Africa. The 84insG
mutation was found only in one patient of Ashkenazi
Jewish extraction, further corroborating the ethnic spec-
ificity of this allele.
A second group included seven previously reported
mutant alleles (IVS2 G[1]rA, R48W, R120W, G377S,
V394L, R463C, and rec NciI) (Beutler and Gelbart
1996). All of them were found in single cases, except
for R463C, which was found twice, and R120W, which
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Figure 4 Detection, by FAMA, of the complex allele rec NciI in a type 3 GD patient’s gene. This complex allele consists of three single-
base substitutions, all involving a cytosine. The L444P mutation (TrC transition) gives rise to C-A and T-G mismatches, whereas C-C and G-
G heteroduplexes are formed at codons 456 and 460 (GrC transversion in both cases). C-A and C-Cmismatches are detected byHAmodification,
whereas the T-G mismatch is revealed by osmium chemistry. G-G mismatches are not detectable. A, Electropherogram of sense strand, after
HA modification (C specific), showing a high peak on the right, which corresponds to the uncleaved PCR amplicon (1,200 bp) encompassing
exon 10, exon 11, and the 3′ UTR. Three additional cleavage peaks indicate the mispaired cytosines on the sense strand (C-A, C-C, and C-C
mismatches). B, Fluorescence profile of antisense strand, after HA modification, revealing two additional cleavage peaks at complementary
positions for codons 456 and 460, corresponding to cytosines on the antisense strand at both C-C heteroduplexes. This illustrates the duplication
of information obtained, from the same gel, by differential end labeling. Because of the large size of the amplicon, a logarithmic scale for the
horizontal axis was used for both panels. Osmium tetroxide reaction resulted in a sixth cleavage peak on the sense strand, revealing the
mismatched thymine of the second heteroduplex (T-G), occurring at codon 444 (TrC transition) (not shown).
was detected in three unrelated patients and was always
associated with the same haplotype (fig. 3). Interestingly,
all three patients originated from Brittany, suggesting a
possible founder effect and the usefulness of screening
for R120W when studying Celtic populations (Ferec et
al. 1992). Alternatively, since the mutation occurred at
a CpG dinucleotide and also is the sequence of the pseu-
dogene, it could be due to a recurrent mutational event
(Choy et al. 1997).
A third group included eight novel mutations distrib-
uted throughout the gene (fig. 2). All but one were mis-
sense mutations. They seem to be functionally impor-
tant, since (1) 5/7 of the substituted amino acids (I119,
R170, N188, K303, and L324) are evolutionarily con-
served in human and mouse acid b-glucosidase (O’Neill
et al. 1989); (2) most of the changes are nonconservative,
with three amino acid substitutions (R170P,N188K, and
K303I) resulting in charge changes and four (R170P,
S237P, L324P, and A446P) introducing the helix-dis-
rupting proline residue; and (3), by use of this highly
sensitive technique, no double mutants (Savov et al.
1995) have been found, other than the complex allele
rec NciI (fig. 4). All these arguments support the view
that these mutations are responsible for enzyme defi-
ciency, which ideally should be confirmed by expression
studies (Grace et al. 1997; Pasmanik-Chor et al. 1997).
Since heterozygote detection based on enzyme assay is
notoriously unreliable, such rare mutations are of par-
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Table 4
Nucleotides at Six Polymorphic Sites in the Previously Known and the Novel
Glucocerebrosidase Haplotypes
HAPLOTYPE
NUCLEOTIDE, AT POLYMORPHIC SITEa
2127
(Intron 4)
[1545]
2840
(Intron 4)
[2251]
3304
(Intron 5)
(2714)
3938
(Intron 6)
[3348]
5147
(Intron 7)
[4552]
6157
(Intron 9)
[5561]
Plus ()b a c g g c g
Minus ()b g g a a a a
Africanb g a a a a a
Uncommon variantb a c g g c g
Pseudogene sequence Del g g Del Del a
Novel haplotype a g a a c g
a Numbers within brackets indicate nucleotide numbering according to Beutler and Gelbart (1996).
Del  deleted.
b Data from the report by Beutler et al. (1992).
ticular value for genetic counseling of families; thesemu-
tations also could be frequent in, up to now, poorly
studied populations. In addition, all elucidated mutants
may prove to be useful for a better understanding of
protein structure and functional activity. The acid b-
glucosidase catalytic domain consists of an (a/b)8 barrel
with conserved functional amino acids at the C-terminal
ends of six of the eight strands constituting the b-barrel
(Henrissat et al. 1995). Of note, the arginine at position
120 is located at the C-terminal end of the b2 strand
and is considered to be crucial for the activation of the
active-site nucleophile Glu340 (Miao et al. 1994; Du-
rand et al. 1997).
Twelve polymorphisms of the GBA gene, which are
distributed in the 5′ sequence and throughout the in-
trons, had been detected previously. Analysis of a large
number of patients disclosed only four haplotypes, re-
vealing a strong linkage disequilibrium (Beutler et al.
1992). During our survey, a novel haplotype, in addition
to the pathogenic mutations, was identified in two pa-
tients carrying different genotypes (table 4). This asso-
ciation analysis with polymorphic markers, made pos-
sible by the broad DNA-scanning window of FAMA,
may provide new information for population genetics.
Genotype/Phenotype Correlations
The genotype/phenotype relationship for all 25 pa-
tients is presented in table 2. On the basis of previous
data and the present study, the following general con-
siderations can be drawn. It appears that GD severity
may be attenuated by the dominant influence of the
N370S mild allele. Nevertheless, although the heteroal-
lelic presence of N370S allows prediction of a nonneu-
ronopathic clinical course (NIH Technology Assessment
Panel on Gaucher Disease 1996), visceral involvement
can be highly variable. The same N370S/R120W ge-
notype was found in three patients who exhibited strik-
ingly different phenotypes, thus underlining the phe-
notypic variation associated with identical genotypes
among unrelated individuals (table 2). Other associa-
tions with the N370S allele (I119T, N188K, S237P, and
L324P) were seen only once. The severity of these novel
alleles, which may determine the individual clinical out-
come, therefore cannot be assessed clearly and can only
be speculated (table 2). However, it should be noted that
hydrophobic cluster analysis predicts an important role
for Ile119 and Ser237, within the catalytic site (Glu235
being the conserved proton donor) (Durand et al. 1997),
in accordance with the severe clinical outcome associated
with their substitution.
The severity of the common L444P was confirmed in
our series, in which two children, homozygous for this
latter mutation, exhibited type 3 GD (table 2), whereas
another L444P/L444P homozygote case was found in
an African neonate originating from Rwanda, who pre-
sented with type 2 GD and died at 18mo of age (authors’
unpublished data, not included in this French series).
Interestingly, the complex allele rec NciI (L444P 
A456P  V460V) was evidenced in patient 21 (fig. 4),
who developed neurological symptoms typical of type 3
GD and who died despite enzyme recombinant therapy.
His complete genotype was characterized as rec NciI/
V394L, thus confirming that the V394L mutation ob-
viously is severe (Beutler and Gelbart 1996).
It is certainly an oversimplification to determine the
severity of a given missense mutation when only the
amino acids involved in the substitution have been con-
sidered. The nature and location of the change must be
considered in relation to the three-dimensional structure,
the active site, or potentially important domains of the
enzyme. The R48W mutation was observed in associ-
ation with L444P, in patient 17. The nonconservative
substitution of tryptophan for arginine, with loss of a
positive charge and introduction of a more sterically
rigid, bulky side chain, could be expected to be delete-
rious. Conversely, a functional approach recently has
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demonstrated that the R48W mutation retains a signif-
icant residual enzymatic activity (Grace et al. 1997). Our
clinical data agree with this study and favor the mild
severity of the R48W allele.
In spite of the general relationship between the in-
herited mutations and the disease manifestations, unex-
plained discrepancies remain. Mutations alone seem un-
able to completely predict the phenotypic expression. A
typical example is the severely affected 22-year-old
woman (patient 25a) and her asymptomatic brother (pa-
tient 25b), who were shown to carry the same homo-
zygous missense mutation, with homozygosity making
the severity of the allele more relevant to study (table
2). Such a phenotypic variation of a simple Mendelian
condition within kindreds emphasizes the influence of
modulating factors. Possible mechanisms involved in or
responsible for phenotypic variation in cases of identical
pathogenic mutations may be multifactorial: they in-
clude additional intragenic sequence alterations, specific
modifier genes (Rozmahel et al. 1996), and the genetic
background in general, as well as the influence of the
environment (Wolf 1997). In this respect, the identifi-
cation of an additional GBA haplotype is interesting,
since the severity of GD may be influenced by a different
genetic background of the GBA gene. Indeed, the influ-
ence of otherwise neutral polymorphisms on pathogenic
mutations recently has been suggested for cystic fibrosis
(Cuppens et al. 1998).
Occurrence of clinical heterogeneity in sibs homozy-
gous for identical pathogenic mutations is puzzling. It
rules out additional intragenic sequence alterations, as
has been suspected (Savov et al. 1995), but favors un-
linked genetic or environmental factors. The role of a
modifier gene(s) acting in cis, as has been proposed re-
cently for flanking genes at the GBA locus (Winfield et
al. 1997), or in trans, as suggested by the striking dif-
ference in phenotypic expression observed within fam-
ilies in our series, remains to be demonstrated formally
in GD (Moran et al. 1997).
In accordance with data emerging for otherMendelian
traits—such as craniosynostosis (Rutland et al. 1995),
cystic fibrosis (Kiesewetter et al. 1993), and even sickle-
cell disease, which is a paradigm for monogenic diseases
(Serjeant 1997)—the role of multifactorial control is fur-
ther emphasized here. Although it is the primary factor,
the mutation does not explain the entire genotype/phe-
notype relationship. A disease phenotype corresponding
to a particular mutation will remain unpredictable until
a more efficient analysis of its genetic expression be-
comes routinely available; this should lead to caution in
genetic counseling. Thus, the Mendelian concept of a
monogenic trait or a monofactorial disease can no longer
be regarded as absolute, since the influence of a multi-
factorial control on the realization of the phenotype is
increasingly being recognized.
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